Similarly, ARL2 protein expression levels were down-regulated in grade IV glioma samples (Fig. 1b, P < 0.05), as well as U251 and U87 cells than non-tumor samples (Additional file 2: Figure S2B, P < 0.001). This evidence concerns the gene ARL2 and central nervous system cancer.